PDL BioPharma, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for life-threatening illness. The company markets three biopharmaceutical products: Cardene IV to reduce high blood pressure during or after surgery; Retavase for the improvement of ventricular function following acute myocardial infarction (AMI), the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI; and IV Busulfex, a chemotherapeutic agent that provides anti-tumor effect to eradicate residual malignancy, ablation of the bone marrow, and immunosuppression to prevent graft rejection. The company also has six product candidates in Phase 2 or Phase 3 clinical development, which include Terlipressin to treat type 1 hepatorenal syndrome; Nuvion for the treatment of Intravenous steroid-refractory ulcerative colitis; Ularitide to treat cute decompensated heart failures; Daclizumab for the treatment of asthma and related respiratory diseases, multiple sclerosis, and to prevent acute kidney transplant rejection; M200 for the treatment of solid tumors; and HuZAF to treat rheumatoid arthritis. PDL BioPharma sells its products through hospital-focused sales force primarily in the United States, Canada, Europe, and Asia. It has collaboration arrangements with Biogen Idec, Inc. The company, formerly known as Protein Design Labs, Inc., was founded in 1986. It changed its name to PDL BioPharma, Inc. in January 2006. PDL BioPharma is headquartered in Fremont, California.
Oversold, comeback expected.
$19.77 (02/08/07)
